Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 3 Semaglutide

NCT07040592 · Recruiting

Last updated 2026-05-28

This clinical trial is testing whether semaglutide, a medication not yet approved for alcohol use disorder, is safe and feasible for people living with HIV who also struggle with alcohol dependence.

Status Recruiting Currently enrolling participants.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design open-label (no blinding) treatment study

Participants 30 people Planned (estimated).

Who can join Ages 18–99 · all sexes

Timeline Started 2026-01 · est. completion 2027-06

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT07040592 ↗

Description as written by the study sponsor.

This study seeks to determine the feasibility, acceptability, and preliminary efficacy of an intervention consisting of off-label use of a medication with strong efficacy data for alcohol use disorder (AUD) with medical management and a clinical pharmacist-delivered behavioral intervention in reducing alcohol use among individuals with HIV and AUD.

Treatments tested

semaglutide Drug

All participants will receive a prescription for semaglutide and will meet with a clinical pharmacist and addiction psychiatrist for further support

Main thing measured	Proportion of participants who complete enrollment and duration of sessions
Sponsor	Yale University
Conditions studied	Alcohol Use Disorder (AUD), HIV
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07040592 ↗